Form 4: Xenetic Biosciences Director Acquires Stock Options

Director Roger D. Kornberg acquired 2,500 stock options in Xenetic Biosciences, Inc.

Summary

• Roger D. Kornberg, a director at Xenetic Biosciences, Inc., acquired 2,500 stock options on December 11, 2024.
• The stock options have an exercise price of $4.24.
• These options vest 100% on the twelve-month anniversary of the grant date.
• The options expire on December 11, 2034.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock option grants, which is neither positive nor negative in itself. It is a neutral event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for company directors and officers who have transactions in the company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across publicly traded companies as a form of compensation and incentive.
• The vesting period of 12 months is also a typical vesting schedule for stock options.
• The 10-year expiration period is also a common practice.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, Xenetic Biosciences, director, XBIO